Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1Phase 1/2 1

Status

Completed 4Terminated 3

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Thoracic 3Tumor-Agnostic 1

Conditions

Small Cell Lung Carcinoma 3Recurrence 1Neoplasms 1Neoplasm Metastasis 1

Interventions

Cyclophosphamide 641Bevacizumab 552Paclitaxel 534Carboplatin 533Cisplatin 480pembrolizumab 454Gemcitabine 422Docetaxel 415Rituximab 386Radiotherapy 373Dexamethasone 351Doxorubicin 330Nivolumab 308Fluorouracil 286Capecitabine 260Etoposide 245Prednisone 244Oxaliplatin 242Erlotinib Hydrochloride 242Cytarabine 233Lenalidomide 232Trastuzumab 226Pemetrexed 220Vincristine 212fludarabine phosphate 208Leucovorin 208Cetuximab 208Filgrastim 204Bortezomib 193Methotrexate 183

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Completed × Has results × rovalpituzumab tesirine × Clear all
NCT02674568 2021-07-30

TRINITY

AbbVie

Phase 2 Completed
342 enrolled 18 charts
Thoracic

Recurrence, Small Cell Lung Carcinoma

NCT03061812 2021-02-23

TAHOE

AbbVie

Phase 3 Completed
444 enrolled 16 charts
Thoracic

Neoplasm Metastasis, Small Cell Lung Carcinoma

NCT03543358 2021-01-05

A Long-Term Study of Rovalpituzumab Tesirine

AbbVie

Phase 2 Completed
3 enrolled 6 charts
Tumor-Agnostic

Neoplasms

NCT01901653 2018-08-09

Rovalpituzumab Tesirine (SC16LD6.5) in Recurrent Small Cell Lung Cancer

Stemcentrx

Phase 1/2 Completed
82 enrolled 28 charts
Thoracic

Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡